EVOLVE
Randomized, Phase III Study of Early Intervention With Venetoclax and Obinutuzumab Versus Delayed Therapy With Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 3
- Enrollment
- 247 patients (estimated)
- Sponsors
- National Cancer Institute (NCI)
- Tags
- BCL-2 Inhibitor, Monoclonal Antibody, CD20, Randomization
- Trial Type
- Treatment
- Last Update
- 2 months ago
- SparkCures ID
- 1945
- NCT Identifier
- NCT04269902
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.